Announcements

We are delighted to share some highly cited Special Issues in 2024 from the “Methods and Technologies Development” Section of Cancers (ISSN: 2072-6694).

The list of highly cited Special Issues can be viewed below:

“Recent Trends in PET/CT Tracer Development and Multimodal Imaging” Guest Editors: Prof. Dr. Olaf Prante and Prof. Dr. Tobias Bäuerle Submission deadline: 30 June 2024	“Radionuclide Therapy and Hybrid Imaging in   Oncology” Guest Editors: Dr. Amir Sabet and Prof. Dr. Frank Grünwald Submission deadline: 29 February 2024
“New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies” Guest Editors: Dr. Ilaria Stefania Pagani, Dr. Hannah Wardill and Dr. Teresa Sadras Submission deadline: 31 January 2024	“The Role of PET Imaging in Oncology: New Advancements in Clinical and Research Setting” Guest Editors: Dr. Pierpaolo Alongi and Dr. Desiree Deandreis Submission deadline: 31 March 2024
“Updates on Imaging of Common Urogenital Neoplasms” Guest Editor: Dr. Athina C Tsili Submission deadline: 29 February 2024	“Recent Advances and Challenges in Breast Cancer Surgery” Guest Editor: Dr. Antonio Piñero-Madrona Submission deadline: 30 April 2024

We invite you to read and submit relevant papers to the journal Cancers using the following link: https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

We cordially invite you to attend the 1st International Online Conference on Hematology organized by the MDPI journals Hematology Reports (ISSN: 2038-8330, Impact Factor 1.2), Hemato (ISSN: 2673-6357, Impact Factor 1.0), and Thalassemia Reports (ISSN: 2039-4365, Impact Factor 1.2). It will take place online from 28 to 30 October 2026, and it is free of charge for all participants.

Conference Chair:

• Prof. Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

The topics of interest:

S1. Multiple Myeloma;
S2. Acute Myeloid Leukemia;
S3. Acute Lymphoblastic Leukemia;
S4. Non-Hodgkin Lymphoma;
S5. Hodgkin Lymphoma;
S6. CML and Myeloproliferative Neoplasms;
S7. Stem Cell Transplantation and New Cellular Therapies;
S8. Rare diseases.

Important dates:
Deadline for abstract submission: 29 June 2026;
Notification of acceptance: 28 July 2026;
Deadline for registration: 22 November 2026.

Guide for authors:
To submit your abstract, please click on the following link: https://sciforum.net/user/submission/create/1493.

To register for the event, please click on the following link: https://sciforum.net/event/IOCHE2026?subscribe&section=#registration.

Note: We only accept abstracts for this conference. To publish a conference proceedings paper for free and submit a full manuscript to the organizing journals Hematology Reports (ISSN: 2038-8330, Impact Factor 1.2), Hemato (ISSN: 2673-6357, Impact Factor 1.0) and Thalassemia Reports (ISSN: 2039-4365, Impact Factor 1.2), please refer to the Publication Opportunities section.

Best Presentation Award and Best Poster Award:

• Six winners;
• Each winner will receive a certificate;
• CHF 200 each.

For any enquiries regarding this event, please contact ioche2026@mdpi.com.

We look forward to seeing you at the 1st International Online Conference on Hematology!

We are delighted to share some highly cited Special Issues in 2024 in the “Cancer Causes, Screening and Diagnosis” Section in Cancers (ISSN: 2072-6694). 

The list of highly cited Special Issues can be seen below: 

1. “Artificial Intelligence in Cancer Screening”
Guest Editors: Prof. Dr. Mario Mascalchi and Dr. Stefano Diciotti
Views: 51900+ | Cited by 220+

2. “Breast Cancer Imaging: Current Trends and Future Direction”
Guest Editor: Prof. Dr. Angela Spanu
Views: 54380+ | Cited by 190+

3. “Innovations in Diagnosis and Treatment of Colon and Rectal Cancer: Preoperative Optimisation, Multidisciplinary Management, and Surgical Technology Advancement”
Guest Editor: Dr. Gianluca Pellino
Views: 47860+ | Cited by 120+

 
4. “Innovations in Soft Tissue Sarcoma Diagnosis and Treatment”
Guest Editors: Dr. Erlinda M. Gordon, Dr. Sant P. Chawla and Dr. Frederick L. Hall
Views: 26250+ | Cited by 60+

5. “Advanced Research in Pancreatic Ductal Adenocarcinoma”
Guesto Editors: Prof. Dr. Stephan Kersting, Prof. Dr. Robert Grützmann and Prof. Dr. Tobias Keck
Views: 37390+ | Cited by 50+

6. “Advances in the Diagnosis, Prognosis and Treatment of Diffuse Large B-cell Lymphoma”
Guest Editor: Dr. Gustavo Tapia
Views: 17770+ | Cited by 40+

You are invited to view and submit relevant papers to the journal Cancers at the following link:

https://www.mdpi.com/journal/cancers. 

Cancers Editorial Office

Cancers (ISSN: 2072-6694) is an open access journal, granting its readers free and unlimited access to all full-text articles. We welcome you to read the following highly cited Special Issues published in 2024 (now closed for submissions) in the “Cancer Biomarkers” Section: 

“Liquid Biopsy for Lung Cancer Treatment”
Guest Editors: Dr. Maria Palmieri and Dr. Frullanti Elisa
Submission deadline: 30 July 2024
Views: 35560+

“New Advances in Urothelial Cancer: Diagnosis, Therapy and Prognosis”
Guest Editors: Prof. Pierfrancesco Bassi and Dr. Giuseppe Palermo
Submission deadline: 13 September 2024
Views: 24090+

“Cancer Biomarkers: Recent Progress, Innovations and Future Clinical Implications”
Guest Editors: Dr. M. Walid Qoronfleh and Dr. Nader Al-Dewik
Submission deadline: 15 November 2024
Views: 36580+

“Advances in Soft Tissue and Bone Sarcoma”
Guest Editors: Dr. Catrin Sian Rutland
Submission deadline: 30 April 2024
Views: 61220+

“Biomarkers in Breast Cancer: Recent Advances and Challenges”
Guest Editors: Dr. Yihong Wang and Prof. Dr. Evgeny Yakirevich
Submission deadline: 30 August 2024
Views: 20630+

“Biomarker in Urologic Cancer”
Guest Editors: Dr. Nessn H. Azawi
Submission deadline: 30 September 2024
Views: 18430+

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

July is Sarcoma and Bone Cancer Awareness Month, and various global activities are aiming to highlight and increase the awareness of sarcoma and bone cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of sarcoma and bone cancer, which were published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings”
by Jun-Ho Kim and Seul Ki Lee
Cancers 2023, 15(6), 1703; https://doi.org/10.3390/cancers15061703
Available online: https://www.mdpi.com/2072-6694/15/6/1703

“Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin”
by Valentina Fausti, Alessandro De Vita, Silvia Vanni, Virginia Ghini, Lorena Gurrieri, Nada Riva, Roberto Casadei, Marco Maraldi, Giorgio Ercolani, Davide Cavaliere et al.
Cancers 2023, 15(4), 1080; https://doi.org/10.3390/cancers15041080   
Available online: https://www.mdpi.com/2072-6694/15/4/1080

“Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis”
by Bikesh K. Nirala, Taku Yamamichi, D. Isabel Petrescu, Tasnuva N. Shafin and Jason T. Yustein
Cancers 2023, 15(20), 5108; https://doi.org/10.3390/cancers15205108  
Available online: https://www.mdpi.com/2072-6694/15/20/5108

“Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?”
by Caleb Kim, Lara E. Davis, Catherine M. Albert, Brian Samuels, Jesse L. Roberts and Michael J. Wagner
Cancers 2023, 15(20), 5044; https://doi.org/10.3390/cancers15205044
Available online: https://www.mdpi.com/2072-6694/15/20/5044

“SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma”
by Erlinda Maria Gordon, Sant P. Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas, Victoria S. Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, Don Arlen Brigham, Ania Moradkhani et al.
Cancers 2023, 15(3), 906; https://doi.org/10.3390/cancers15030906  
Available online: https://www.mdpi.com/2072-6694/15/3/906

“Application of Machine Learning for Differentiating Bone Malignancy on Imaging: A Systematic Review”
by Wilson Ong, Lei Zhu, Yi Liang Tan, Ee Chin Teo, Jiong Hao Tan, Naresh Kumar, Balamurugan A. Vellayappan, Beng Chin Ooi, Swee Tian Quek, Andrew Makmur et al.
Cancers 2023, 15(6), 1837; https://doi.org/10.3390/cancers15061837  
Available online: https://www.mdpi.com/2072-6694/15/6/1837

“Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group”
by Bettina Jansko-Gadermeir, Michael Leisch, Franz J. Gassner, Nadja Zaborsky, Thomas Dillinger, Sonja Hutter, Angela Risch, Thomas Melchardt, Alexander Egle, Manuel Drost et al.
Cancers 2023, 15(8), 2305; https://doi.org/10.3390/cancers15082305
Available online: https://www.mdpi.com/2072-6694/15/8/2305

“Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin”
by Margherita Cortini, Francesca Macchi, Francesca Reggiani, Emanuele Vitale, Maria Veronica Lipreri, Francesca Perut, Alessia Ciarrocchi, Nicola Baldini and Sofia Avnet
Cancers 2023, 15(4), 1221; https://doi.org/10.3390/cancers15041221  
Available online: https://www.mdpi.com/2072-6694/15/4/1221

“Deep Learning Approaches to Osteosarcoma Diagnosis and Classification: A Comparative Methodological Approach”
by Ioannis A. Vezakis, George I. Lambrou and George K. Matsopoulos
Cancers 2023, 15(8), 2290; https://doi.org/10.3390/cancers15082290
Available online: https://www.mdpi.com/2072-6694/15/8/2290

“Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design”
by Bradford S. Hoppe, Ivy A. Petersen, Benjamin K. Wilke, Todd A. DeWees, Reiko Imai, Eugen B. Hug, Maria Rosaria Fiore, Jürgen Debus, Piero Fossati, Shigeru Yamada et al.
Cancers 2023, 15(6), 1660; https://doi.org/10.3390/cancers15061660
Available online: https://www.mdpi.com/2072-6694/15/6/1660

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

According to the World Health Organization, cancer is a leading cause of mortality and accounted for approximately 10 million deaths in 2020. Therefore, continued research regarding understanding, diagnosing, and treating cancer is a global priority. The ever-evolving field of oncology spans innovations and discoveries in tumor biology, immunotherapy, targeted treatments, early detection, and personalized medicine.

The mission of MDPI’s cluster of oncology-related journals is to publish high-impact research with potential to redefine cancer treatment and care. Addressing topics from solid tumors to hematologic malignancies, from rare cancers to novel therapeutics, these journals provide a dynamic platform for groundbreaking discoveries and clinical advancements that shape the future of oncology.

The four participating journals are as follows:

• Cancers (ISSN: 2072-6694) focuses on publishing high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics. In particular, it showcases the most seminal studies in the rapidly growing areas of immunology, immunotherapy, and tumor microenvironment research. Cancers is led by its Editor-in-Chief, Prof. Dr. Samuel C. Mok;
• Current Oncology (ISSN: 1718-7729) is dedicated to advancing cancer care and therapy via publishing clinically relevant research with direct applications to oncology practice. Since its establishment in 1994, the journal has played an important role in disseminating new knowledge across the entire cancer care continuum, spanning the prevention, early detection, and diagnosis of cancer; treatment, including systemic therapy, radiation therapy, and surgery; supportive care; and survivorship care. Additionally, it highlights the critical role of biomarkers and biomarker-driven research in guiding personalized oncology. Affiliated with several key cancer societies, Current Oncology provides a global platform to share scientific progress in oncology. The journal is led by its Editor-in-Chief, Prof. Dr. Shahid Ahmed;
• Onco (ISSN: 2673-7523) functions as a scientific forum integrating novel preclinical, translational, and clinical cancer research and is focused on (but not limited to) the following topics: cancer cell signaling; cancer genetics and molecular targets; cancer epigenetics and heterogeneity; carcinogenesis and cancer evolution; microbiomes and cancer; cancer metabolomics; cancer biomarkers; cancer dormancy; novel targeted and immune cancer therapies; randomized clinical trials; oncotargets; cancer therapies; and clinical reports proposing novel therapeutic regimens. Onco is led by its Editor-in-Chief, Dr. Constantin N. Baxevanis;
• Targets (ISSN: 2813-3137) is centered on, but not limited to, discovering novel molecules which act as diagnostic biomarkers and therapeutic targets, establishing new bionic recognition systems for biosensing and bioimaging, developing novel approaches for biomarker detection, related applications of biological interaction monitoring and targeted therapy, designing new signal amplification strategies for biosensing and cellular or in vivo imaging, utilizing molecular recognition for single-molecule or single-cell analysis, elucidating new pathways or mechanisms in disease development and progression, and synthesizing smart nanomaterials for activatable imaging and responsive drug release. Targets is led by its Editor-in-Chief, Prof. Dr. Huangxian Ju.

MDPI’s mission and values:

As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access—All our content is published in open access format and distributed under a Creative Commons License, providing free access to the latest research and allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency—We rapidly publish novel research through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
• Simplicity—We offer user-friendly tools and services on our integrated system to enhance the efficiency of our editorial process;
• High-Quality Service—We support scholars and their work by providing a range of options, such as publication in journals at mdpi.com, early publication at preprints.org, and the publication of conferences at sciforum.net, to positively impact research;
• Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open-science practices.

Selected Topics:

• “Cancer Biology and Radiation Therapy: 2nd Edition”;
• “Hepatobiliary and Pancreatic Diseases: Novel Strategies of Diagnosis and Treatments”;
• “Biomarkers of Disease: Discovery and Clinical Applications”;
• “Recent Advances in Anticancer Strategies, 2nd Edition”.

Selected Articles:

Cancers
“Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment”
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171

Current Oncology
“Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse”
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179

Onco
“Significance of PET/CT Imaging in Myeloma Assessment: Exploring Novel Applications beyond Osteolytic Lesion Detection and Treatment Response”
Onco 2024, 4(1), 15-36; https://doi.org/10.3390/onco4010002

Targets
“Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review”
Targets 2024, 2(2), 104-125; https://doi.org/10.3390/targets2020007

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue	quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article
	Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue	green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article
	Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue	ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article
	Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue	computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article
	Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue	sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article
	Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue	bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article

MDPI will be attending the 10th World Congress of the International Academy of Oral Oncology, which will be held from 16 to 19 July 2025 at the Arena and Conference (ACC) Liverpool in Liverpool, UK.

The International Academy of Oral Oncology (IAOO) is a multi-disciplinary community of clinicians and scientists working on issues relating to the etiopathogenesis, epidemiology, prevention and management or oral and perioral tumours of oral disease in patients with malignancies. The IAOO exists to bring together clinicians and scientists working in the field of oral oncology, so that advances in medical science can be achieved and quickly translated into benefits for patients.

The World Congress of the Academy is an opportunity for the IAOO community to meet and exchange ideas and innovations in the field of oral oncology. The Congress is the only global gathering of head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, otorhinolaryngologists and all other allied specialists in oral cancer care.

The following open access journals will be represented at the conference:

• Cancers;
• CMTR;
• Current Oncology;
• Gastrointestinal Disorders;
• Oral;
• Surgeries.

If you are planning to attend, please do not hesitate to visit our booth. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://eu.eventscloud.com/website/14087/home/.

International Albinism Awareness Day 2025 underscores the urgent need for increased awareness, preventive care, and accessible healthcare for people with albinism. This year’s theme highlights the life-threatening impact of skin cancer among individuals with albinism and reinforces the importance of sun protection, early detection, and timely treatment.

Albinism is a rare, inherited genetic condition that affects the body’s ability to produce melanin, the pigment responsible for the color of our skin, hair, and eyes. People with albinism typically have very light skin and hair, alongside various vision impairments. While it is not contagious and does not affect intelligence, albinism is often misunderstood. This leads to stigmatization, discrimination, and even human rights violations in some regions where harmful myths persist.

Because they have little to no melanin, individuals with albinism are especially vulnerable to sun damage and face a significantly increased risk of developing skin cancer. Addressing this requires more than just clinical intervention—it calls for integrated healthcare policies and inclusive social systems that acknowledge both the medical and socio-political dimensions of the condition.

In recognition of this global observance, we invite you to explore a curated collection of articles and Special Issues from selected MDPI journals, including Biomedicines, Cancers, Children, Diagnostics, Genes, International Journal of Molecular Sciences, Journal of Clinical Medicine and Molecules. These open-access resources provide critical insights into the diagnosis, management, and complications of albinism, and promote cross-disciplinary collaboration between researchers, clinicians, and advocacy groups.

Together, through science, education, and empathy, we can foster a more inclusive world where people with albinism live free from discrimination and with access to the care they deserve.

“Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?”
by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee and Jay E. Self
Diagnostics 2025, 15(11), 1395; https://doi.org/10.3390/diagnostics15111395

“Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients”
by Olga Shchagina, Anna Stepanova, Polina Mishakova, Vitaliy Kadyshev, Nina Demina, Ludmila Bessonova, Sofya Ionova, Daria Guseva, Andrey Marakhonov, Rena Zinchenko et al.
Biomedicines 2024, 12(10), 2234; https://doi.org/10.3390/biomedicines12102234

“Functional Characterization of Splice Variants in the Diagnosis of Albinism”
by Modibo Diallo, Cécile Courdier, Elina Mercier, Angèle Sequeira, Alicia Defay-Stinat, Claudio Plaisant, Shahram Mesdaghi, Daniel Rigden, Sophie Javerzat, Eulalie Lasseaux et al.
Int. J. Mol. Sci. 2024, 25(16), 8657; https://doi.org/10.3390/ijms25168657

“Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report”
by Mirjana Bjeloš, Ana Ćurić, Mladen Bušić, Benedict Rak and Biljana Kuzmanović Elabjer
Int. J. Mol. Sci. 2024, 25(12), 6442; https://doi.org/10.3390/ijms25126442

“Missing Heritability in Albinism: Deep Characterization of a Hungarian Albinism Cohort Raises the Possibility of the Digenic Genetic Background of the Disease”
by Nikoletta Nagy, Margit Pal, Jozsef Kun, Bence Galik, Peter Urban, Marta Medvecz, Beata Fabos, Alexandra Neller, Aliasgari Abdolreza, Judit Danis, Viktoria Szabo, Zhuo Yang, Stefanie Fenske, Martin Biel, Attila Gyenesei, Eva Adam and Marta Szell
Int. J. Mol. Sci. 2024, 25(2), 1271; https://doi.org/10.3390/ijms25021271

“Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?”
by Line Kessel, Christine Dahlgren Bohnsack Kjølholm and Joaquim Torner Jordana
Children 2023, 10(12), 1910; https://doi.org/10.3390/children10121910

“Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation”
by Kristian Lisbjerg, Joaquim Torner Jordana, Vibeke N. Brandt, Christine Kjølholm and Line Kessel
J. Clin. Med. 2023, 12(17), 5451; https://doi.org/10.3390/jcm12175451

“Skin Pigmentation Types, Causes and Treatment—A Review”
by Amin Mahmood Thawabteh, Alaa Jibreen, Donia Karaman, Alà Thawabteh and Rafik Karaman
Molecules 2023, 28(12), 4839; https://doi.org/10.3390/molecules28124839

“Report of Hermansky–Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes”
by Sadeeda Qaiser Zaman, Muhammad Anas, Gauhar Rehman, Qadeem Khan, Aiman Iftikhar, Mashal Ahmad, Muhammad Owais, Ilyas Ahmad, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem et al.
Genes 2023, 14(1), 145; https://doi.org/10.3390/genes14010145

“Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population”
by Kyle S. Chan, Brenda L. Bohnsack, Alexander Ing, Andy Drackley, Valerie Castelluccio, Kevin X. Zhang, Hanta Ralay-Ranaivo and Jennifer L. Rossen
Genes 2023, 14(1), 135; https://doi.org/10.3390/genes14010135

“More than Skin Deep—Latest Advances in Congenital and Autoimmune Pigmentation Disorders” Guest Editor: Prof. Dr. Reinhart M. Speeckaert Submission deadline: 25 August 2025	“Melanin Pigmentation: Physiology and Pathology” Guest Editors: Prof. Dr. Shosuke Ito and Prof. Dr. Manickam Sugumaran Submission deadline: 20 October 2025